Accelerating Clinical Trials (ACT) Consortium

The ACT Canada Consortium consists of hundreds of investigators, stakeholders, and highly qualified research personnel from 11 trial units and 28 research networks across Canada. The central guiding principle of the ACT Consortium is that its activities will accelerate, optimize, and facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials (RCTs) to improve health in Canada and around the world.

CANet is one of the many networks that is supported by ACT which allows CANet Network Investigators to apply for research monies and in-kind support for clinical trials.

ACT is providing research personnel to our Network to improve our infrastructure support and further our Network activities. Examples of in-kind support include insurance for clinical trials, assistance with identification and activation of research centres internationally, amongst others.

Consortium Highlights

  • ACT brings together hundreds of researchers from 28 networks, 11 trial units, patient-partners, the biotechnology industry, government, and experts in research ethics review processes, contracts, insurance, regulatory processes, patient engagement, clinical trials training, communications, knowledge mobilization – from Nova Scotia to British Columbia and Nunavut.
  • ACT will maximize research impact and knowledge mobilization – following best practices in patient-oriented research and integrated knowledge translation, leveraging national and international contacts.
  • ACT will advance equitable access to trials for all Canadians – no matter where they live, inclusive of gender, ethnicity, and socioeconomic status – following the principles of equity, diversity, and inclusion in clinical trials such that the knowledge gained is applicable to all those affected.
  • ACT will build clinical trial capacity – providing trial units with the knowledge, skills, and experience to conduct large-scale trials. We will streamline administrative processes (for example, ethics reviews, contracts, and protocols) to accelerate timelines and reduce costs.

To learn more about ACT, visit

Call for Proposals


ACT has recently announced the first Call for Proposals: Supporting the Completion of High-Impact Randomized Controlled Trials.

A total of $2 million dollars is available for this competition. The maximum funding per application is $200,000.

CANet will only be allowed to support 3 submissions in this competition.

If you intend to apply, you must send your full application to CANet by Friday, March 24, 2023 (11:59 PM Pacific Time) to Kevin O’Neil at [email protected].

Those selected to proceed to the full application will be provided with a letter of support from CANet before ACT’s deadline of April 3, 2023.

First Annual ACT Canada Consortium Meeting

The First Annual ACT Canada Consortium Meeting will be held at the Hamilton Convention Centre in Hamilton, ON, on April 17th-18th, 2023.

This meeting will spotlight presentations on Canadian Biotechnology and include themed breakout sessions aimed at furthering Canadian research partnerships between Canadian Biotechnology companies and Canadian Clinical Trialists. 

Please contact Dr. Ratika Parkash at [email protected] if you are interested in learning more about this initiative or if you would like to attend the meeting.